Category: Cancer Treatment

The NFL and Cancer Treatment Centers Of America Announce Prostate Cancer Screening Partnership

It was recently announced that the National Football League Alumni Association will collaborate with the Cancer Treatment Centers of America to increase awareness for men on the topic of prostate cancer. Prostate cancer is one of the most popular forms of cancer that men are diagnosed with. As a result of the collaboration, men over the age of 40 will be eligible to receive a free prostate screening.

The Prostate Pep Talk campaign will feature famous NFL coaches talking about the risks of prostate cancer. The special announcements will take place during Prostate Cancer Awareness Month. Research done by the American Cancer Society shows that there will be over 100,000 new prostate cancer diagnosis every year. Important factors to pay attention to are race and family history.

There will be a national kick off press conference at the NFL Films Studio. Among those scheduled to attend are former NFL head coach Herman Edwards, Emmy Award winner Beasley Reece and Sean Cavanaugh, the Chief of Radiation Oncology at The Cancer Treatment Centers of America. There will also be events in Chicago and Phoenix.

Cavanaugh notes that screening can potentially stop prostate cancer. The Cancer Treatment Centers of America are excited to work with the NFL in order to increase awareness about different screening techniques and treatment options. Cavanaugh wants men to be aware that a less than normal screening does not mean that the cancer has developed.

Men can schedule their screening through Prostate Pep Talk. The testing will be done at LabCorp’s service centers. The NFL and CTCA are confident that their partnership will help improve the lives of men throughout the United States.

Based out of Florida, the Cancer Treatment Centers of America are a group of hospitals that treat patients who have been diagnosed with cancer. CTCA uses different treatment options, such as radiation and chemotherapy.

Visit More :

The Exceptional Cancer Treatment Centers of America

Current world health statistics show that cancer is the world leading killer disease. Richard J Stephenson opened the first Cancer Treatment Center of America in 1988. His mother had passed on after ailing from cancer. Richard aimed at giving cancer patients specialised care. This first centre was at Midwestern Regional Medical Center in Zion, Illinois. This was only the beginning of the growth as between 2005 and 2012 four other Cancer Treatment Centers of America (CTCA) opened up.

The headquarters for CTCA is in Boca Raton having been moved from Schaumburg, Illinois. These centres serve cancer patients all over the USA. They are also opened for international patients. CTCA use various methods to treat and cure cancer patients ranging from radiation, chemotherapy, surgery and immunotherapy. They also give therapies to manage the side effects of the different treatment methods.

Prostate cancer is the leading cancer that affects men. To intensify the knowledge and why early screening is vital; Cancer Treatment Centers of America, LabCorp and the National Football League of Alumni have come together. This is to increase awareness among men and give them access to screening. This campaign aims to reach 2000 men who are 40 years old and meet other criteria to be signed up for a free Prostate Specific Antigen. This will be done by LabCorp. After this exercise, other men will get this at $25 which is a discounted price.

This campaign will also include talks from famous NFL head coaches like Bill Cowher, Herm Edwards and Dick Vermeil through public announcements. These announcements will be aired through September which is prostate cancer awareness month and will be national. This will go along away to encourage men to get screened. To kick-start these campaigns there will be a press conference which will feature Edwards and Beasley Reece. In attendance also will be Jon Runyan, an advocate for cancer awareness and Mike Quick whose father dealt with prostate cancer.

Visit More :

Cancer Treatment Centers of America

Cancer Treatment Centers of America is a national profit maximization network of five hospitals that helps cancer patients across the United States. It follows a complete approach to cancer protection using different medical strategies such as surgery, chemotherapy, radiation, and immunotherapy to treat cancer. It also offers divertive homogenous checkups to manage side effects such as pain,nausea, fatigue, malnutrition, extreme nervousness and melancholy.

Richard J Stephenson established the organization after his mother died of cancer. He was not impressed by the kind of cancer treatments that were in existence during the time of his mother’s condition. Lack of a better treatment option pushed him to open the first hospital at Midwestern Regional Medical Center in Zion, Illinois back in the year 1988. Other four hospitals were formed and opened between 2005 and 2012. All this was to pursue cancer treatment.

Different types of cancer occur in various parts of the Human Body. Prostate cancer is one type of cancer that has continued to increase tremendously among men. Divergent organizations such as National Football League AlumniAssociation and LabCorp in collaboration with Cancer Treatment Centers of America have teamed up to educate men and keep them aware of prostate cancer. These agencies have worked tirelessly to help people access the cancer screenings smoothly and efficiently.

Experts in the field of cancer advise that men should begin to access the cancer screenings at the beginning of age 40. Other organizations have continued to hold press conferences and campaigns to raise the awareness and general knowledge of likelihood risks of prostate cancer. The attacks have significantly influenced men to get screened for cancer to enable early recognition of their status.

Survivors of cancer such as Carl Baylor have been in the limelight to educate people on prostate cancer and mobilize the people especially men for screening. Different schedules for the cancer awareness campaigns are issued in different parts of the United States which will be affiliated with Cancer Treatment Centers of America in various cities across the nation.

Visit More :

Cancer Treatment Centers Of America Join Forces With NantHealth And Allscripts To Upgrade Cancer Treatment Protocols

Cancer Treatment Centers of America is teaming up with the companies NantHealth and Allscripts to develop solutions that will enable Eviti, a support solution manned by NantHealth electronic records from Allscripts. This Clinical Pathways program will aid in keeping patients informed of their own treatment process while allowing the physician’s workflow to be uninterrupted. The platform that will power this program is known as the NantOS and was designed with input from oncologist numbering in the hundreds.

The Clinical Pathways system will make available all feasible options in regards to treatment and eliminate any need for guesswork on the part of the physician. Patients, who will now be better informed of their own treatment options will also be afforded the opportunity to be more active in making decisions pertaining to treatment options.

CTCA first began talks with NantHealth and Allscripts in 2016 to begin planning the Clinical Pathways project. The final product provides a host of features that are equally beneficial to both patient and physician:

About CTCA
• Treatment routines customized to fit the specific needs of patients.
• Direct comparison of factors vital to the choosing of treatment options
• Safe and efficient tap screen computer orders
• Access to drug reaction and toxicity reports
• Extensive support provided by way of clinical data
• Functions in real time

Cancer Treatment Centers Of America is a five-facility network of clinics throughout America that treat patients fighting cancer. CTCA makes effective use of traditional cancer treatment options while adding to the mix an assortment of therapy options to relieve the pain and discomfort associated with many of these traditional treatment options.

CTCA was first started in 1998 by Richard J. Stephenson and the operation is based in Boca Raton, Florida. The five cancer treating clinics maintained by the company are located in Zion, Illinois, Tulsa, Oklahoma, Philadelphia, Pennsylvania, Goodyear, Arizona, and Newman, Georgia.

Read More Click Here

Research in Oncotarget Suggests New Cancer Treatment Options

Cancer has been one of the most pressing medical issues in human history. Since the early years of modern medicine, oncologists and medical practitioners have been fooled by the resilience of malignant cells in the human body. These cells result in a wide range of health issues, including melanoma, leukemia, and other forms of cancer. Cancer is prevalent in every society to varying degrees. Therefore, cultural traits, dietary habits, and environmental factors cannot be blamed for all cases of cancer.While many researchers aim to discover the causes of cancer, some oncologists hope to learn the mechanisms of cancer cell replication. By discovering the processes of replication, researchers can find weaknesses. These weaknesses can be exploited for treatment options. These research efforts have led to several breakthroughs in recent years. For example, oncologists have discovered how to improve chemotherapy treatments for lung cancer patients by isolating certain biomarkers. These discoveries are promising for the future of oncology, but cancer remains a deadly disease.In most cases, cancer can be treated effectively in early-stage patients. For doctors to detect early-stage cancers, patients must visit their medial practitioner for routine examinations.

Unfortunately, many people prefer to avoid these examinations. In the future, technology may improve early-detection rates.If malignant cells are not destroyed during the early stages of cancer, a patient’s probability of survival decreases. Survival rates are extremely low for patients who have malignant cells that developed into stage four cancer. Consider the example of breast cancer. During the early stages of breast cancer, the tumors can simply be removed via surgery. This is not the case for late-stage breast cancer. Malignant cells tend to spread rapidly. When this happens, tumors can develop in numerous organs across the body.In these dire cancer cases, the chances of survival are slim. This is because oncologists do not have an effective means of neutralizing the disease. Surgery remains an option, but malignant cells are difficult to remove in some organs. For many late-stage patients, chemotherapy is the only viable treatment option. Chemotherapy is considered to be a blunt treatment. Some cancers can resist chemical and radiation treatments. Chemotherapy treatments can also result in extreme side-effects. It is clear that researchers need to discover new treatment options that are effective at all stages of cancer.

Searching for an Cancer’s Achilles’ Heel

To discover an effective treatment option for serious forms of cancer, oncologists must find a weakness in the replication process of malignant cells. If doctors can halt the replication of malignant cells, they can stop the spread of cancers in patients. This kind of discovery would be groundbreaking.Many researchers refer to this kind of weakness as the Achilles’ heel of cancer. In Greek mythology, Achilles was a warrior who was nearly invincible. To his opponents, Achilles was immune to physical harm. However, Achilles lost his invincibility when his heel was struck by an arrow. Achilles’ only weakness was exploited, and he perished during the sacking of Troy.The story of Achilles is appropriate for the field of oncology. In many cases of late-stage cancer, malignant cells seem invincible. Despite numerous chemotherapy and surgery treatments, relapse often occurs in late-stage patients. Researchers hope to find the weakness that will remove the replication abilities of malignant cells. This discovery would allow doctors to use less invasive options. Furthermore, patients could expect higher rates of success. This would eventually reduce the stress associated with cancer diagnoses.

Researchers Discover a Critical Weakness

While findings have not evolved into practical treatment options, some researchers may have discovered the Achilles’ heel of cancer cells. Garth Owens, an oncology researcher, analyzed several articles published in the journal Oncotarget in 2016 and 2016. In his statements about the existence of an Achilles’ heel for cancer, Owens acknowledged that the replication process of non-coding RNA is unknown in mainstream medicine. He believes that medical professionals must understand this process to eradicate cancer.Mainstream oncology has not deciphered the secrets of cancer, but recent papers published in Oncotarget present potential weaknesses in malignant cells. These weaknesses deal with oligonucleotides.Oligonucleotides are polynucleotides that have a small number of nucleotides. These kinds of polynucleotides are short RNA or DNA molecules. Their functions are not fully understood by oncologists, oligonucleotides are important in the field of genetics.Researchers learned that oligonucleotides can be applied to non-coding mitochondrial RNA. This application curbs tumor development in numerous pre-clinical models. Researchers also learned that the application of oligonucleotides to non-coding mitochondrial RNA can prevent metastasis.This breakthrough was discovered by the Burzio research team in 2009. While analyzing the nucleus of a sperm cell, the Burzio team noticed an odd relationship between non-coding mitochondrial RNA and cancer. This relationship deals with the splicing and ligation of 16S sense and antisense RNA. In biology, sense RNA refers to a strand that is translatable into protein. Antisense RNA refers to a non-coding strand of RNA that complements mRNA.The researchers compared healthy sperm nuclei to cancerous counterparts. The Burzio research team discovered that different structures were present in the samples. In malignant cells, the stem-loop structures are altered. Due to extreme variations in the stem-loop structures, the antisense transcripts are nearly undetectable. It is important to note that the antisense transcripts are still present. The minimal presence of the antisense transcripts can be credited to a process of down-regulation.If the antisense transcripts continued to be down-regulated, the cancer cells would be forced to enter a death cycle. This cellular mechanism is akin to a self-destruction process. With this knowledge, the Burzio research team aimed to exploit this down-regulation weakness.

A New Way to Eliminate Cancer Cells

By triggering the down-regulation process in the antisense transcripts of cancer cells, the Burzio team hoped to kill malignant cells. To study the viability of a down-regulation treatment, the researchers experimented with mice. The researchers started the experiment by dividing a large sample of mice into two groups. Both groups of mice were injected with melanoma. After the melanoma developed in the mice, the antisense transcripts were identified. The control group did not receive a treatment. However, each mouse in the treatment group was treated with the oligonucleotide application.After the initial treatments, the researchers observed the results. In the control group, the malignant cells remained prevalent. This result was unsurprising. Every subject of the control group died by day 25 of the experiment. The treatment group’s results were shocking. Due to the treatment of oligonucleotide, every member of the treatment group survived until the end of the experiment at day 120.The treatment group was euthanized and examined at the end of day 120. The researchers noted that every mouse that received the down-regulation treatment had no traces of lung or liver metastasis. While the researchers were impressed by these findings, they needed to determine if the results could be extrapolated to other cancers. They received similar results from a renal cell carcinoma model.Down-regulation treatments have not been used in human clinical trials, but the results are promising. The future of oncology is bright.

About Oncotarget

Oncotarget is a free-to-read oncology journal. All papers that are published in the journal are reviewed by a board of editors. The editors are leading researchers at key universities in Europe, North America, and Asia.The founders of Oncotarget believe that information should be free and accessible. They accomplish this mission by using a model that does not rely on paywalls or subscriptions.